TG Therapeutics to present initial Phase 1 azer-cel results in primary progressive multiple sclerosis at MSToronto2026

• TG Therapeutics set late-breaking October 23 MSToronto2026 disclosure of initial Phase 1 TG-Azercel-101 results for azer-cel in PPMS.
• Data have not yet been presented; full late-breaking abstract text is scheduled for release October 21.
• Presentation will frame early clinical experience for an allogeneic CD19 CAR T approach in progressive MS, a high-need segment.
• Meeting slate also includes multiple BRIUMVI updates spanning long-term outcomes, real-world use, dosing changes, and a subcutaneous program.
• Flow of new readouts signals continued lifecycle expansion efforts for BRIUMVI while the company advances azer-cel into clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006884842) on October 08, 2026, and is solely responsible for the information contained therein.